Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6Other hematologic neoplasm 3Sarcoma 1Plasma cell 1

Conditions

Dendritic Cell Sarcoma, Interdigitating 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine phosphate 20Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 18Cyclophosphamide 17Mycophenolic Acid 14Cyclosporine 12Busulfan 12Antilymphocyte Serum 10Melphalan 9Tacrolimus 8Etoposide 6Methotrexate 5Thiotepa 4Radiotherapy 4Methylprednisolone 4Cord Blood Stem Cell Transplantation 3Carboplatin 3Alemtuzumab 3thymoglobulin 2Therapeutics 2Sirolimus 2Rituximab 2In Situ Hybridization, Fluorescence 2Filgrastim 2Drug Therapy 2Cytarabine 2Carmustine 2venetoclax 1sargramostim 1pirtobrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × pirtobrutinib × Sarcoma × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡